Track topics on Twitter Track topics that are important to you
The WHO estimates that the largest number of new tuberculosis (TB) cases in 2008 occurred in the South-East Asia Region, which accounted for 34% of incident cases globally. However, the estimated inci...
KIACTA™ (also known as eprodisate) is an orally bioavailable small molecule intended for the treatment of AA amyloidosis, an orphan indication that results from long-standing inflammatory cond...
Anthrax is a zoonotic disease caused by the spore-forming bacterium Bacillus anthracis. The disease most commonly occurs in mammals (e.g., cattle, sheep, goats, camels, antelope. Anthrax occurs in hu...
AUT00063 develpoed by Autifony Therapeutics, is a novel, orally active small molecule designed to selectively modulate Kv3 potassium channels, which are important in central auditory processing. Pre...
BioPortfolio has launched a number of Facebook pages to allow our visitors to keep track with latest news, published paper and clinical trials by lead biotechnology and healthcare topics:- &nbs...
Summit Therapeutics PLC and Orexigen Therapeutics are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, in...
CRISPR Therapeutics, a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, and Casebia Therapeutics, a joint-venture established by CRISPR Therapeut...
Tuesday, June 27th 2017 at 11:00am UTC — Company Expands Executive Leadership Team with Key Appointments in Early 2017 — CAMBRIDGE, Mass.–(BUSINESS WIRE)– RaNA Therapeutics tod...
CAMBRIDGE, Mass. and BASEL, Switzerland, July 10, 2017 (GLOBE NEWSWIRE) — CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines...
Bioverativ Therapeutics has reached an agreement to acquire clinical-stage biotechnology company True North Therapeutics.
Dragonfly Therapeutics has appointed Nicolai Wagtmann as its chief scientific officer (CSO).
Akcea Therapeutics plans to raise up to $100m through an initial public offering of its common stock shares.
Spero Therapeutics has announced it has raised $51.7m in a series C financing round led by GV (formerly Google Ventures).